Very late relapse of acute promyelocytic leukemia 17 years after continuous remission

Masatoshi Sakurai, Shintaro Watanuki, Jun Kato, Risa Hashida, Yusuke Yamane, Daiki Karigane, Takayuki Mitsuhashi, Mitsuru Murata, Hironori Ueno, Tomonori Nakazato, Shinichiro Okamoto, Takehiko Mori

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


The prognosis of acute promyelocytic leukemia (APL) has been improved by the combination of all-trans retinoic acid (ATRA) with chemotherapy. Nonetheless, relapse occurs in a certain proportion of patients, mostly within three to four years after treatment. We herein report a patient treated with ATRA and chemotherapy achieving remission who relapsed approximately 17 years after the treatment. A literature review identified 5 additional reported cases of APL relapse after more than 10 years. None of them presented with generally established risk factors for relapse, such as a high leukocyte count. The potential for late relapse of APL occurring more than 10 years after treatment should be recognized.

Original languageEnglish
Pages (from-to)3299-3302
Number of pages4
JournalInternal Medicine
Issue number22
Publication statusPublished - 2018


  • Acute promyelocytic leukemia
  • All-trans retinoic acid
  • Late relapse

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Very late relapse of acute promyelocytic leukemia 17 years after continuous remission'. Together they form a unique fingerprint.

Cite this